tirzepatide and type 1 diabetes Groundbreaking Trial Testing for Protecting the hearts of people

12,15 GLP-1 RAs have been licenced (at higher doses than those used for diabetes) for the treatment of obesity

Studies of orforglipron (Foundayo) showed significant and sustained weight loss (at least 10% of starting weight) over 72 weeks

However, participants who had a history of, or met criteria for, conduct disorder, bipolar disorder, mania, or schizophrenia were excluded

Research also connects glutathione deficiency to cardiovascular disease, metabolic disorders, neurodegenerative conditions, and immune dysfunction

And more importantly, how do you know if its the right fit for your body, lifestyle, and health goals